Abstract
Background and Objectives: Lymph node management in cutaneous melanoma has undergone a paradigm shift, transitioning from routine complete lymph node dissection (CLND) to a more selective, individualized approach. This narrative review explores the historical evolution, current evidence and clinical guidelines surrounding lymphadenectomy for a patient with Stage III of melanoma. Materials and Methods: A comprehensive literature search was conducted across PubMed, Scopus and Web of Science, focusing on randomized controlled trials, meta-analyses and updated international guidelines published in the past 15 years. Results: Traditional surgical approaches favored radical lymphadenectomy for regional disease control. However, pivotal trials such as the Multicenter Selective Lymphadenectomy Trial II (MSLT-II) and German Dermatologic Cooperative Oncology Group Selective Lymphadenectomy Trial (DeCOG-SLT) demonstrated no survival advantage from immediate CLND following a positive sentinel lymph node biopsy (SLNB), underscoring increased surgical morbidity. Consequently, guidelines from Associazione Italiana di Oncologia Medica (AIOM), the European Society for Medical Oncology (ESMO), and the National Comprehensive Cancer Network (NCCN) now endorse SLNB as the standard for nodal staging, reserving CLND for select high-risk cases. Conclusions: The role of lymphadenectomy in melanoma is increasingly becoming selective, shaped by tumor burden, nodal involvement and response to systemic therapy. SLNB remains central to staging and treatment planning, while CLND is no longer routine. Continued clinical trials and integration with immunotherapy will further refine surgical strategies in melanoma care.